SCHEMBL8154035

SCHEMBL8154035

CCC(=O)C(C)NC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140648 1.00
SCHEMBL14306757 1.00
SCHEMBL16454939 0.80 ANPEP (0.33)
SCHEMBL20978336 0.78
SCHEMBL14260134 0.78
SCHEMBL24060748 0.76 ALDH1A1 (0.43)
SCHEMBL15314084 0.76
SCHEMBL14361058 0.76
SCHEMBL21690499 0.76 TDP1 (0.35)
SCHEMBL16327591 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298097-A1 Peptide Derivatives and Uses Thereof NOSOPHARM (FR) 2017-10-19 US disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 US disclosed
US-20160324923-A1 APOLIPOPROTEIN A-I MIMICS CERENIS THERAPEUTICS HOLDING SA (FR) 2016-11-10 US disclosed
US-9388232-B2 Apolipoprotein A-I mimics CERENIS THERAPEUTICS HOLDING SA (FR) 2016-07-12 US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 US disclosed
US-20150141330-A1 APOLIPOPROTEIN A-I MIMICS CERENIS THERAPEUTICS HOLDING SA (FR) 2015-05-21 US disclosed
US-8993597-B2 Apolipoprotein A-I mimics CERENIS THERAPEUTICS HOLDING SA (FR) 2015-03-31 US disclosed
US-20140309426-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) 2014-10-16 US disclosed
US-8841347-B2 Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use UNIWERSYTET JAGIELLONSKI (PL) 2014-09-23 US disclosed
US-8633251-B2 Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use UNIWERSYTET JAGIELLONSKI (PL) 2014-01-21 US disclosed
US-20130289118-A1 DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE UNIWERSYTET JAGIELLONSKI (PL) 2013-10-31 US disclosed
US-20130231459-A1 APOLIPOPROTEIN A-I MIMICS CERENIS THERAPEUTICS HOLDING SA (FR) 2013-09-05 US disclosed
EP-2318377-B1 PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH INC (US) 2013-08-21 EP disclosed
US-20110028562-A1 DERIVATIVES OF AMINOALKANOLS, METHOD OF OBTAINING OF AMINOALKANOLS AND THEIR USE UNIWERSYTET JAGIELLONSKI (PL) 2011-02-03 US disclosed
WO-2010148006-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed
EP-1054909-A1 POLYMERISATION CATALYST COMPONENT BP Chemicals Limited (GB) 2000-11-29 EP disclosed
WO-1999042492-A1 POLYMERISATION CATALYST COMPONENT BP CHEMICALS LIMITED (GB) 1999-08-26 WO disclosed